{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:35:51Z","timestamp":1784118951488,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in the management of type 2 diabetes mellitus (T2DM) and obesity. While these medications offer glycemic control and cardiovascular benefits, the risks have increased because of their potential impact on cancer risk, particularly colorectal cancer (CRC). This meta-analysis aimed to evaluate the association between GLP-1 RAs and CRC risk in patients receiving GLP-1 RAs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study was conducted the PRISMA guidelines. Electronic databases (PubMed, Embase, Cochrane Library Web of Science, and ClinicalTrials.gov) were searched from inception to December 2024. The inclusion criteria encompassed Studies analyzing the effects of GLP-1 RA on CRC risk in patients with T2DM. The Newcastle-Ottawa Scale was used for the quality assessment of the included cohort studies. Random-effects models were employed for the pooled analysis, and heterogeneity was evaluated using the I2 statistic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seven retrospective cohort studies involving 5,066,681 patients were included. The pooled analysis revealed a significantly increased risk of CRC among patients receiving GLP-1 RAs (RR, 2.31; 95% CI, 1.82\u20132.93; I2\u2009=\u200936%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). However, the incidence of CRC was not significantly associated with GLP-1 RA use compared with other drugs (OR, 1.73; 95% CI: 0.21\u201314.18, <jats:italic>p<\/jats:italic>\u2009=\u20090.61; I2\u2009=\u2009100%). Quality assessment indicated a low-to-moderate risk of bias across the included studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Overall, this study suggests a significantly increased risk of colorectal cancer associated with GLP-1 RA use in patients receiving GLP-1 RAs. However, the incidence of CRC is not considerably high. These findings highlight the need for further long-term, large-scale clinical trials to elucidate the relationship between GLP-1 RAs and cancer risk. Clinicians should consider these results when prescribing GLP-1 RAs, particularly in patients with CRC risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s12876-025-04211-4","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:00:00Z","timestamp":1755846000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies"],"prefix":"10.1186","volume":"25","author":[{"given":"Ying","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"10","key":"4211_CR1","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1093\/cvr\/cvab249","volume":"117","author":"EW Lehmann","year":"2021","unstructured":"Lehmann EW, Torekov SS. Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance? Cardiovasc Res. 2021;117(10):e120-2.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"4211_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, Vilsb\u00f8ll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14(7):390\u2013403.","journal-title":"Nat Rev Endocrinol"},{"key":"4211_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20:5\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"4211_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art. Mol Metab. 2021;46: 101102.","journal-title":"Mol Metab"},{"key":"4211_CR5","doi-asserted-by":"publisher","first-page":"170749","DOI":"10.1016\/j.peptides.2022.170749","volume":"151","author":"A Mayendraraj","year":"2022","unstructured":"Mayendraraj A, Rosenkilde MM, Gasbjerg LS. GLP-1 and GIP receptor signaling in beta cells\u2013a review of receptor interactions and co-stimulation. Peptides. 2022;151:170749.","journal-title":"Peptides"},{"issue":"9548","key":"4211_CR6","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705.","journal-title":"Lancet"},{"issue":"4","key":"4211_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to\u2010head comparisons of glucagon\u2010like peptide\u20101 receptor agonists. Diabetes Obes Metab. 2016;18(4):317\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"4211_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Reviews Endocrinol. 2012;8(12):728\u201342.","journal-title":"Nat Reviews Endocrinol"},{"issue":"2","key":"4211_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1517\/14740338.2015.987122","volume":"14","author":"A Consoli","year":"2015","unstructured":"Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207\u201318.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 2","key":"4211_CR10","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.2337\/dcS13-2004","volume":"36","author":"MA Nauck","year":"2013","unstructured":"Nauck MA, Friedrich N. Do GLP-1\u2013based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245.","journal-title":"Diabetes Care"},{"issue":"3","key":"4211_CR11","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4211_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108535","author":"I Zafar","year":"2025","unstructured":"Zafar I, Unar A, Khan NU, Abalkhail A, Jamal A. Molecular biology in the exabyte era: taming the data deluge for biological revelation and clinical transformation. Comput Biol Chem. 2025. https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108535","journal-title":"Comput Biol Chem"},{"key":"4211_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092025","author":"T Sawicki","year":"2021","unstructured":"Sawicki T, Ruszkowska M, Danielewicz A, Nied\u017awiedzka E, Ar\u0142ukowicz T, Przyby\u0142owicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13092025.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4211_CR14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets. 2021;22(9):998\u20131009.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"4211_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683\u201391.","journal-title":"Gut"},{"issue":"1","key":"4211_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2174\/1573399819666230413094200","volume":"20","author":"A Kumar","year":"2024","unstructured":"Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in india: A review of IDF diabetes atlas 10th edition. Curr Diabetes Rev. 2024;20(1):105\u201314.","journal-title":"Curr Diabetes Rev"},{"issue":"8","key":"4211_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103110","volume":"18","author":"M-H Keivanlou","year":"2024","unstructured":"Keivanlou M-H, Amini-Salehi E, Sattari N, Hashemi M, Saberian P, Prabhu SV, Javid M, Mirdamadi A, Heidarzad F, Bakhshi A. Gut microbiota interventions in type 2 diabetes mellitus: an umbrella review of glycemic indices. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2024;18(8): 103110.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"issue":"1","key":"4211_CR18","doi-asserted-by":"publisher","first-page":"E180","DOI":"10.2174\/0115733998284844240102110559","volume":"21","author":"M-H Keivanlou","year":"2025","unstructured":"Keivanlou M-H, Amini-Salehi E, Hassanipour S, Zare R, Mohammadi-Vajari E, Hashemi M, Salari A, Porteghali P. The value of microbiome-targeted therapy on lipid indices of patients with type 2 diabetes mellitus: an umbrella meta-analysis of randomized controlled trials. Curr Diabetes Rev. 2025;21(1):E180-124225761.","journal-title":"Curr Diabetes Rev"},{"key":"4211_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103363","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, Yu OH, Peters TM, Eisenberg MJ. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions. eClinicalMedicine. 2025. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103363.","journal-title":"eClinicalMedicine"},{"issue":"1","key":"4211_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1\u2013based therapies. Gastroenterology. 2011;141(1):150\u20136.","journal-title":"Gastroenterology"},{"issue":"7","key":"4211_CR21","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.2337\/db12-1686","volume":"62","author":"AE Butler","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595\u2013604.","journal-title":"Diabetes"},{"key":"4211_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1515797","volume":"13","author":"X Huang","year":"2025","unstructured":"Huang X, Wu Y, Ni Y, Xu H, He Y. Global, regional, and national burden of type 2 diabetes mellitus caused by high BMI from 1990 to 2021, and forecasts to 2045: analysis from the global burden of disease study 2021. Front Public Health. 2025;13: 1515797.","journal-title":"Front Public Health"},{"issue":"2","key":"4211_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol. 2024;10(2):256\u20138.","journal-title":"JAMA Oncol"},{"issue":"10","key":"4211_CR24","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1097\/MPA.0000000000002197","volume":"51","author":"A Krishnan","year":"2022","unstructured":"Krishnan A, Hadi Y, Hutson WR, Thakkar S, Singh S. Glucagon-like peptide 1\u2013based therapies and risk of pancreatic cancer in patients with diabetes and obesity. Pancreas. 2022;51(10):1398\u2013403.","journal-title":"Pancreas"},{"key":"4211_CR25","doi-asserted-by":"publisher","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R. Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology. 2024. https:\/\/doi.org\/10.1053\/j.gastro.2024.04.029.","DOI":"10.1053\/j.gastro.2024.04.029"},{"issue":"3","key":"4211_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2015.02.005","volume":"21","author":"JA Koehler","year":"2015","unstructured":"Koehler JA, Baggio LL, Yusta B, Longuet C, Rowland KJ, Cao X, Holland D, Brubaker PL, Drucker DJ. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab. 2015;21(3):379\u201391.","journal-title":"Cell Metab"},{"issue":"2","key":"4211_CR27","first-page":"564","volume":"3","author":"R Khatoon","year":"2025","unstructured":"Khatoon R, Ghani M, Shahzad S, Siddiqa M, Azmat M, Zafar I, Shafiq S. Phytochemical profiling and bioactive potential of momordica balsamina seed extracts for antidiabetic activity and antioxidant potential. Indus J Biosci Res. 2025;3(2):564\u201376.","journal-title":"Indus J Biosci Res"},{"key":"4211_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12020-019-02055-z","volume":"66","author":"C Cao","year":"2019","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine. 2019;66:157\u201365.","journal-title":"Endocrine"},{"key":"4211_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Group P-P: preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4:1\u20139.","journal-title":"Syst Reviews"},{"issue":"1","key":"4211_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1):1\u201310.","journal-title":"BMC Health Serv Res"},{"key":"4211_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M. Newcastle-ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:1\u20135.","journal-title":"BMC Med Res Methodol"},{"key":"4211_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1070-0","volume":"8","author":"L Schmidt","year":"2019","unstructured":"Schmidt L, Shokraneh F, Steinhausen K, Adams CE. Introducing RAPTOR: revman parsing tool for reviewers. Syst Rev. 2019;8: 1\u20134.","journal-title":"Syst Rev"},{"key":"4211_CR33","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00228-016-2068-3","volume":"72","author":"PT Htoo","year":"2016","unstructured":"Htoo PT, Buse JB, Gokhale M, Marquis MA, Pate V, St\u00fcrmer T. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. Eur J Clin Pharmacol. 2016;72:1013\u201323.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4211_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","volume":"47","author":"J Wang","year":"2022","unstructured":"Wang J, Kim CH. Differential risk of cancer associated with glucagon-like peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47(1):18\u201325.","journal-title":"Endocr Res"},{"key":"4211_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2024.20.10_suppl.402","author":"TYJ Hsieh","year":"2024","unstructured":"Hsieh TYJ, Lu C, Lee G-Y, Wei JC-C. Comparative analysis of GLP-1 receptor agonists versus metformin on cancer outcomes in patients with polycystic ovarian syndrome: a real-world multi-center cohort study in the United States. JCO Oncol Pract. 2024. https:\/\/doi.org\/10.1200\/OP.2024.20.10_suppl.402.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"4211_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","volume":"29","author":"D Abrahami","year":"2018","unstructured":"Abrahami D, Yin H, Oriana H, Pollak MN, Azoulay L. Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. Epidemiology. 2018;29(2):246\u201353.","journal-title":"Epidemiology"},{"key":"4211_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001514","author":"Y Sun","year":"2024","unstructured":"Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024. https:\/\/doi.org\/10.1097\/JS9.0000000000001514","journal-title":"Int J Surg"},{"issue":"7","key":"4211_CR38","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305\u20132421305.","journal-title":"JAMA Netw Open"},{"key":"4211_CR39","doi-asserted-by":"publisher","unstructured":"Figlioli G, Piovani D, Peppas S, Pugliese N, Hassan C, Repici A, Lleo A, Aghemo A, Bonovas S. Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2024. https:\/\/doi.org\/10.1016\/j.phrs.2024.107401.","DOI":"10.1016\/j.phrs.2024.107401"},{"key":"4211_CR40","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fimmu.2016.00154","volume":"7","author":"T Zietek","year":"2016","unstructured":"Zietek T, Rath E. Inflammation meets metabolic disease: gut feeling mediated by GLP-1. Front Immunol. 2016;7:154.","journal-title":"Front Immunol"},{"issue":"11","key":"4211_CR41","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41575-018-0025-6","volume":"15","author":"PD Cani","year":"2018","unstructured":"Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671\u201382.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"4211_CR42","first-page":"1534365","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhang X, Chai S, Zhao X, Ji L. Risk of malignant neoplasia with glucagon-like peptide\u20101 receptor agonist treatment in patients with type 2 diabetes: a meta\u2010analysis. J Diabetes Res. 2019;2019(1):1534365.","journal-title":"J Diabetes Res"},{"issue":"5","key":"4211_CR43","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","volume":"43","author":"Y Nakatani","year":"2017","unstructured":"Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, Yasu T, Harasawa H. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43(5):430\u20137.","journal-title":"Diabetes Metab"},{"issue":"10","key":"4211_CR44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","volume":"9","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957\u201364.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4211_CR45","doi-asserted-by":"crossref","unstructured":"Camilleri M, Lupianez-Merly C. Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. Am J Gastroenterol. 2022:10.14309.","DOI":"10.14309\/ajg.0000000000002519"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04211-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04211-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:25:16Z","timestamp":1757445916000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04211-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4211"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04211-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read and approved the article for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}